Author

Pedro Rocha

Vall d'Hebron Hospital UniversitariORCID 0000-0003-3221-7354Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Pedro Rocha1 paper · National Institutes of Health

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Research Focus:differential expression· 3 Organism:human· 3 Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell-cell communication· 1

Frequent Co-Authors

Carl Michael GayiD· 3 shared Catherine Allison StewartiD· 3 shared Jing WangiD· 3 shared John Victor HeymachiD· 3 shared Kavya RamkumariD· 3 shared Lauren A. ByersiD· 3 shared Lixia DiaoiD· 3 shared Yuanxin XiiD· 3 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Carl Michael GayORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologyJournal of Thoracic OncologyPeer-reviewedApr 20, 2026

YAP1 defines an emergent, plastic population of relapsed small cell lung cancer

Catherine Allison Stewart, Kavya Ramkumar, Runsheng Wang…·Carl Michael Gay

This study identifies YAP1-positive cells in relapsed SCLC that exhibit drug tolerance and transition from SCLC to LCNEC-like features, losing some targets but gaining others.

8 citationstop 1%

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologyMolecular CancerPeer-reviewedMar 20, 2025

DNA damage response signatures are associated with frontline chemotherapy response and routes of tumor evolution in extensive stage small cell lung cancer

Benjamin B. Morris, Simon Heeke, Yuanxin Xi…·Lauren A. Byers

This study identifies three distinct DDR phenotypes in SCLC associated with chemotherapy response and tumor evolution.

9 citations

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologyClinical Cancer ResearchPeer-reviewedAug 16, 2024

YAP1 status defines two intrinsic subtypes of LCNEC with distinct molecular features and therapeutic vulnerabilities

Catherine Allison Stewart, Lixia Diao, Yuanxin Xi…·Carl Michael Gay

25 citationstop 4%

humanbulk RNA-seq

𝕏 PostBluesky